Literature DB >> 15233937

Genetic modification of T lymphocytes for adoptive immunotherapy.

Claudia Rossig1, Malcolm K Brenner.   

Abstract

Adoptive transfer of T lymphocytes is a promising therapy for malignancies-particularly of the hemopoietic system-and for otherwise intractable viral diseases. Efforts to broaden the approach have been limited by the physiology of the T cells themselves and by a range of immune evasion mechanisms developed by tumor cells. In this review we show how genetic modification of T cells is being used preclinically and in patients to overcome these limitations, by incorporation of novel receptors, resistance mechanisms, and control genes. We also discuss how the increasing safety and effectiveness of gene transfer technologies will lead to an increase in the use of gene-modified T cells for the treatment of a wider range of disorders.

Entities:  

Mesh:

Year:  2004        PMID: 15233937     DOI: 10.1016/j.ymthe.2004.04.014

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  26 in total

1.  Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts.

Authors:  Sid P Kerkar; Pawel Muranski; Andrew Kaiser; Andrea Boni; Luis Sanchez-Perez; Zhiya Yu; Douglas C Palmer; Robert N Reger; Zachary A Borman; Ling Zhang; Richard A Morgan; Luca Gattinoni; Steven A Rosenberg; Giorgio Trinchieri; Nicholas P Restifo
Journal:  Cancer Res       Date:  2010-07-20       Impact factor: 12.701

2.  Anti-GD2 Strategy in the Treatment of Neuroblastoma.

Authors:  Richard K Yang; Paul M Sondel
Journal:  Drugs Future       Date:  2010       Impact factor: 0.148

3.  Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice.

Authors:  Jennifer A Westwood; Mark J Smyth; Michele W L Teng; Maria Moeller; Joseph A Trapani; Andrew M Scott; Fiona E Smyth; Glenn A Cartwright; Barbara E Power; Dirk Hönemann; H Miles Prince; Phillip K Darcy; Michael H Kershaw
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

4.  4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies.

Authors:  Syam Tammana; Xin Huang; Marianna Wong; Michael C Milone; Linan Ma; Bruce L Levine; Carl H June; John E Wagner; Bruce R Blazar; Xianzheng Zhou
Journal:  Hum Gene Ther       Date:  2010-01       Impact factor: 5.695

5.  CD28 co-stimulation via tumour-specific chimaeric receptors induces an incomplete activation response in Epstein-Barr virus-specific effector memory T cells.

Authors:  B Altvater; S Pscherer; S Landmeier; V Niggemeier; H Juergens; J Vormoor; C Rossig
Journal:  Clin Exp Immunol       Date:  2006-06       Impact factor: 4.330

Review 6.  Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.

Authors:  Bipulendu Jena; Gianpietro Dotti; Laurence J N Cooper
Journal:  Blood       Date:  2010-05-03       Impact factor: 22.113

7.  Stable gene transfer and expression in human primary T cells by the Sleeping Beauty transposon system.

Authors:  Xin Huang; Andrew C Wilber; Lei Bao; Dong Tuong; Jakub Tolar; Paul J Orchard; Bruce L Levine; Carl H June; R Scott McIvor; Bruce R Blazar; Xianzheng Zhou
Journal:  Blood       Date:  2005-09-27       Impact factor: 22.113

Review 8.  Immunomodulation in the treatment of haematological malignancies.

Authors:  Michela Cesco-Gaspere; Emma Morris; Hans J Stauss
Journal:  Clin Exp Med       Date:  2009-02-24       Impact factor: 3.984

9.  Inhibition of p38 MAPK activity in B-NHL Raji cells by treatment with engineered CD20-specific T cells.

Authors:  Lei Jiang; Kang Yu; Jimei DU; Wuhua Ni; Yixiang Han; Shenmeng Gao; Haiying Li; Jianbo Wu; Yihu Zheng; Yingxia Tan
Journal:  Oncol Lett       Date:  2011-05-13       Impact factor: 2.967

10.  IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy.

Authors:  Christian S Hinrichs; Rosanne Spolski; Chrystal M Paulos; Luca Gattinoni; Keith W Kerstann; Douglas C Palmer; Christopher A Klebanoff; Steven A Rosenberg; Warren J Leonard; Nicholas P Restifo
Journal:  Blood       Date:  2008-02-14       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.